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the CC BY-NC-ND license (http://creaAbstract Prostate cancer (PCa) is one of the most lethal cancers in western countries.
Androgen receptor (AR) signaling pathway plays a key role in PCa progression. Despite the
initial effectiveness of androgen deprivation therapy (ADT)for treatment of patients with
advanced PCa, most of them will develop resistance to ADT and progress to metastatic castra-
tion resistant prostate cancer (mCRPC). Constitutively transcriptional activated AR splice var-
iants (AR-Vs) have emerged as critical players in the development and progression of mCRPC.
Among AR-Vs identified to date, AR-V7 (a.k.a. AR3) is one of the most abundant and frequently
found in both PCa cell lines and in human prostate tissues. Most of functional studies have been
focused on AR-V7/AR3 and revealed its role in regulation of survival, growth, differentiation
and migration in prostate cells. In this review, we will summarize our current understanding
of regulation of expression and activity of AR-Vs in mCRPC.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Prostate cancer (PCa) is the second most lethal cancer in
men [1]. Patients with localized PCa do not develop a life-
threatening syndrome and are curable by either surgery or
radiation treatment. However, those with more advanced
metastasis PCa have only very limited treatment options.
Androgen deprivation therapy (ADT) is the standard
treatment for metastatic PCa. Unfortunately, a majority of
patients will relapse and inevitably develop moreand.edu (Y. Qiu).
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tivecommons.org/licenses/by-nc-aggressive metastatic castration resistant prostate cancer
(mCRPC). Though there are few FDA approved treatment
options for mCRPC (i.e., taxane compound, abiraterone,
enzalutamide and sipuleucel-T), drug resistance will
eventually develop. There is no effective treatment for
relapsed mCRPC to date [2]. Therefore, there is an urgent
need to better understand molecular basis of the devel-
opment, progression, and drug resistance of mCRPC.
Androgen receptor (AR) plays a key role in PCa progression.
AR is a transcription regulator belonging to the nuclear
receptor family and is the major mediator of androgen
signaling in prostate cells. It consists of an N-terminal
transactivation domain, a DNA binding domain, a hingeon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
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stabilized by molecular chaperone heat shock protein 90
(HSP90) in the cytoplasm. Upon androgen (i.e., testos-
terone and dihydrotestosterone) binding, AR dissociates
from HSP90, forms a homodimer and translocates into the
nucleus. Once in the nucleus, it binds to androgen response
element (ARE) in the regulatory region of its target genes
and modulates their expression [4,5]. One of AR target
genes prostate specific antigen (PSA) is currently the most
sensitive and widely used biomaker monitoring the pres-
ence, progression and therapeutic responses in PCa [4,6].
More importantly, it is well-known that androgen-AR
pathway contributes to PCa cell proliferation, inhibits
apoptosis, and promotes metastasis [4]. Thus, inhibition of
AR function by ADT therapy is a first-line treatment of
advanced PCa patients.
1. Expression and activity of AR splice
variants (AR-Vs)
1.1. Expression of AR-Vs
In recent years, AR-Vs have emerged as potential important
players in PCa progression and therapeutic resistance.
Since 2008, more than a dozen of AR-Vs lacking the ligand
binding domain have been identified from human PCa cell
lines and xenografts [7e12]. The updated lists of AR-Vs are
summarized in previous reviews [12,13]. These AR-Vs
attracted much attention in the field due to their ligand-
independent transcription activity. The presence of these
AR-Vs transcripts in human prostate tissues have been
validated by RT-PCR and RNA-seq [8,10,14]. Among them,
AR-V7/AR3 is the only variant whose protein expression has
been detected in human prostate tissues using isoform
specific antibodies [8,10]. The relative abundance of AR-
V7/AR3 transcript appears to be highest among various
AR-Vs detected in human prostate tissues [8,14]. It should
be noted that the cryptic exon utilized in AR-V7 (Exon 3-
CE3) or AR3 (Exon 3b) is also detectable in benign tissues
[8,14], suggesting that this variant may also have a func-
tional role in normal prostate. In general, AR-Vs have higher
expression in more aggressive and metastatic tumor
derived cell lines and xenograft models [8,10,11]. Among
AR-Vs, AR-V7/AR3 and ARV567es appear to have relatively
higher expression level than other isoforms. Hu et al.’s
RT-PCR data showed that expression level of AR-V7/AR3
was significantly higher in mCRPC patients than in
hormone-naive PCa patients [10]. To further characterize
the expression profile of AR-V7/AR3, Guo et al. [8] devel-
oped a polyclonal antibody specific for AR3/AR-V7. In
consistence with Hu et al.’s data, immunohistochemistry
analysis revealed that AR3/AR-V7 expression is significantly
increased in more malignant PCa tissues. Interestingly, it
was observed that AR3 expression redistributed from basal
and stromal cells to luminal epithelial cells with the
increasing aggressiveness of PCa. In addition, the staining
also showed that nuclear translocation of AR3 is signifi-
cantly increased in mCRPC patient samples compared with
hormone-naive PCa samples [8]. These studies suggested a
potential functional activation of AR-V7/AR3 during PCa
progression.Bone is the primary site where metastatic PCa spreads. A
recent clinical report showed that transcripts of AR variants
(AR-V1, AR-V7/AR3, and ARV567es) were increased in PCa
bone metastasis. The higher expression of AR-V7/AR3 and
ARV567es in bone metastasis was associated with poorer
prognosis [15]. The correlation of AR-Vs and other impor-
tant parameters in PCa were also monitored. It is well
known that PSA level after castration is a prognostic
biomarker for distal metastasis. KaplaneMeier analysis
indicated that patients with higher AR3 cytoplasmic stain-
ing usually have higher PSA recurrence and lower overall
survival probability [8]. A more recent study on a larger
cohort of patients further validated the importance of AR-
Vs, especially AR-V7/AR3, in metastatic PCa and CPRC
[16]. They compared AR-V7/AR3 expression among three
patient groups (localized PCa n Z 100, newly diagnosed
metastatic PCa n Z 104, and mCRPC n Z 46). The number
of AR-V7/AR3 positive patients was significantly larger in
newly diagnosed metastatic PCa group compared to local-
ized PCa group. This rate increased more dramatically
when comparing mCRPC to localized PCa. More impor-
tantly, the data revealed that the presence of AR-V7/AR3
was associated with shorter survival [16]. Thus, these
studies suggest a strong link between AR-Vs and PCa pro-
gression. A recent study further support that AR-V7/AR3 is
related to and valuable for clinical application. It showed
that AR-V7/AR3 can be detected in circulating tumor cells
from mCRPC patients. Patients with higher AR-V7/AR3
expression in circulating tumor cells had shorter PSA
progression-free survival [17]. These findings suggest that
AR-V7/AR3 may serve as a prognostic and predictive
biomarker for metastasis PCa patients.
It has been well documented that transcription of AR
genes is elevated upon androgen derivation possibly due to
relief of negative feed-back regulation by AReFL [18,19].
The relative increase of AR-Vs compared to AReFL in CRPC
could be resulted from change of splicing factors, RNA
binding proteins, microRNAs [19e22]. RNA splicing factors
U2AF65 and ASF/SF2 were shown to be critical for
AR-V7/AR3 splicing under androgen deprivation condition
[19]. RNA binding protein Sam68 could distinctly regulate
AReFL and AR-Vs transcription. Exogenous expression of
Sam68 was significantly elevated AR-V7/AR3, but not
AReFL transcript levels [21]. In addition, epigenetic factors
such as microRNAs are also involved AR-Vs transcript pro-
duction. MiR-124 directly targeted AR-V4 and AR-V7/AR3
and downregulated their expression [22]. Thus, the
expression of AR-Vs are likely regulated at multiple levels
including transcriptional, posttranscriptional as well as
posttranslational.
1.2. Regulation of AR-Vs activity
Although AR-Vs are shown to be able to regulate canonical
AR target genes, it is still under debate whether AR-Vs have
distinct functions or just serve as a substitute for AR-FL
under androgen depleted condition [8,10,23]. Some studies
suggest that the presence of AReFL is critical for activation
of AR-Vs. It has been shown that expression of AR-Vs
regulated genes could be repressed by either ligand bind-
ing domain-targeted compound or AReFL siRNA knockdown
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AReFL in AR-Vs’ function [24]. It was showed that AReFL
and AR-Vs formed a heterodimer mediated by DNA-binding
domain and by N- and C-termini of AR-V and AReFL,
respectively. The dimerization seemed to be required for
the function of AR-V. Mutants disrupting AR-V and AReFL
interaction diminished AR-V’s transactivation and reduced
growth rate of AR-V positive androgen-independent PCa
cells [24]. This study suggests that though AR-Vs are
constitutively active, they might still need the presence of
AReFL to exert their functions. However, such kind of study
could not exclude the possibility that mutation of the FxxLF
motif of AR-V may also compromise its ability to interact
with other co-factors essential for its transcriptional ac-
tivity. On the other hand, some studies suggest that AR-Vs
may also exert its unique function independent of AReFL
in addition to their overlapping activity. Two studies have
shown that selective knock-down of AR variants in CWR-R1
cells caused the changes of a unique subset of genes that
are not affected by selective knockdown of AReFL [8,25]. It
is also reported that AR-Vs is resistant to pharmacological
inhibition of ligand binding domain of AReFL. Specific
knocking down of AR-Vs, but not AReFL, had dramatically
effects on canonical AR pathway genes expression under
pharmacological inhibition [25]. A more recent report
revealed that AR-V7/AR3 was capable of promoting PCa
migration and sphere-formation under the condition that
exogenous expression of AR3/AR-V7 alone in AR-negative
PCa cells (PC3/DU145) by upregulating genes involved in
epithelial-mesenchymal transition (EMT) [26]. This is
consistent with a study in genetic modified mouse model in
which AR3/AR-V7 is targeted expressed in mouse epithelial
cells using the ARR2PB promoter [27]. In this mouse model,
overexpression of AR3/AR-V7 in luminal epithelial cells
appeared to antagonize the terminal differentiation pro-
cess driven by AReFL by promoting EMT. Perhaps, whether
AR-Vs require AReFL for their activity may very likely
depend on cell context.
Currently, it is conceivable that AR-Vs are critical for
maintaining AR transcriptomes under androgen deficient
conditions. However, whether AR-Vs could initiate a distinct
transcription program in addition to replacing AReFL func-
tion to promote androgen independent PCa growth is still
under debate. Several groups tried to identify AR-Vs regu-
lated genes. Guo et al. [8] performed microarray analysis to
compare AReFL and AR-V7/AR3 regulated genes in PCa cells
selectively knocking down AR-V or AReFL. They showed that
71 genes were commonly regulated by both AReFL and AR3
and 117 genes were preferentially regulated by AR-V7/AR3
but not AReFL. Furthermore, their also identified novel
ARE sites in the AKT1 regulatory regions by chromatin
immunoprecipitation (ChIP) assay. These ARE sites were
preferentially occupied by AR-V7/AR3 but not AReFL.
Interestingly, a study to compare AR binding sites in mCRPC
and androgen-responsive PCa revealed a program shift of AR
binding. Cell cycle regulator UBE2C is one of the top score
targets of AR under androgen independent condition. In this
study, the AR binding sites were identified by chromatin
immunoprecipitation sequencing (ChIP-seq) analysis using
an antibody recognizing the N-terminal part of AR which is
common for both AReFL and AR-Vs [28]. A follow up study
using AR-V7/AR3 specific antibody validated the specificbinding of UBE2C promoter by AR-V7/AR3 but not AReFL
under androgen depleted conditions [29]. In consistence
with the ChIP assay, transient expression of exogenous
AR-V7/AR3 preferentially modulated cell-cycle regulated
genes. The expression of cell-cycle gene UBE2C appears to
be correlated with AR-V7/AR3, but not AReFL in both PCa
cells and clinical mCRPC specimens [30]. However, in a later
study, Li et al. [25] performed gene set enrichment anal-
ysis (GSEA) to examine the response of the identified
“AR-V-specific” M-phase-genes in CWR-R1 cells. They found
that AR-V regulated M-phase gene set was positively-
enriched in androgen-induced AR gene signature derived
from CWR-R1 cells. They also performed GSEA with gene
expression datasets derived from LNCaP cells in response to
different dose of dihydrotestosterone (DHT). Interestingly,
the AR-V signature was positively enriched in the 1 nmol/L
DHT dataset, but negatively enriched in the 100 nmol/L DHT
dataset. They concluded that those mitotic genes appeared
to be unique AR-V targets under androgen depleted condi-
tions may reflect the proliferative events driven either by
AR-Vs or androgen-stimulated AR. In addition, it has been
showed that AR-Vs may bind to its unique targets indepen-
dently of AReFL, but coordinate with AReFL on regulating
canonical AR target genes [29]. In addition, distinct roles of
AR-Vs might be attributed to their ability of binding of
unique mediators. It has been shown that MED1 can be
co-immunoprecipitated with ARV567es independently of
AReFL. ARV567es and P-MED1 co-occupies on the regulatory
regions of UBE2C genes and promotes UBE2C expression
independently of androgen [31]. Another report showed
that RNA-binding protein Sam68 interacts with AR-V7/AR3
and enhances its transcriptional activity [21].
It is well established that ligand binding promotes AR to
dissociate from chaperone HSP90 in the cytoplasm and
translocate to the nucleus. However, AR-Vs only contain a
portion of nuclear localization sequence (NLS) and lack the
C-terminal AR dimerization domain and HSP90 binding
domain. It is conceivable that the nuclear translocation
mechanism of AR-Vs might differ from that of AReFL
[8,32,33]. It was showed that AR-Vs nuclear localization
was independent on AReFL and canonical HSP90 chaperone
shuttling [34]. Recent studies revealed that microtubule-
stabilizing taxane compound was capable of inhibiting nu-
clear translocation and transcriptional activity of AReFL
[35,36]. The subcellular localization of AReFL was associ-
ated with the patients’ response to taxane chemotherapy
[37]. On the other hand, AR-V was shown to be associated
with microtubules to a much less extent than AReFL.
Several studies showed that nuclear translocation of AR-
V7/AR3 was independent on microtubule motor protein
dynein while AReFL does [32,37]. Instead, a study has
shown that nuclear translocation of AR-V7/AR3 can be
inhibited by an import in b inhibitor [38]. These data sug-
gest that nuclear translocation and activation of AR-Vs
might be modulated by different mechanisms. More
importantly, because nuclear localization and activity of
AR-V7/AR3 is not inhibited by standard taxane chemo-
therapy, it is likely that AR-V7/AR3 may play a greater role
in mCRPC after taxane treatment [32]. Along the same line,
nuclear localized AR-V7/AR3 is able to trans-active canon-
ical and non-canonical AR pathway genes and promotes PCa
growth under androgen depleted conditions [8,10,29,34].
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therapeutic resistance
2.1. Transcription regulation
It is conceivable that AR-Vs play important roles in PCa
progression and promote castration resistant growth.
Overexpression of AR-V7/AR3 in AR-Vs negative PCa cells
promoted cell growth under androgen depleted conditions.
Knocking down of AR-V7/AR3 in AR-Vs positive PCa cells
significantly attenuated cell growth [8]. As mentioned
above, in addition to the canonical AReFL regulated genes,
AR-Vs may regulate a subset of M-phase genes under
androgen deprivation conditions. Gene set enrichment
analysis indicated that AR-V7/AR3 is capable of inducing
the expression of cell-cycle related genes. UBE2C is one the
cell-cycle genes specifically regulated by AR-V7/AR3 under
androgen depleted conditions. AR-V7/AR3, but not AReFL,
binds to the regulatory regions of UBE2C and promotes it
expression [29,30]. The expression correlation between
UBE2C and AR-V7/AR3 has also been confirmed in clinical
samples [30]. On the other hand, genes regulated by AReFL
are primarily related to biosynthesis, metabolism and
secretion [30]. In parallel with this finding, knockdown of
AR-V7/AR3 significantly reduced DNA synthesis while
apoptosis was unaffected. In contrast, knockdown of
AReFL promoted apoptosis [8]. The effect of AR-V7/AR3 on
cell growth is partially contributed by AR-V7/AR3 specific
regulation of serine/threonine kinase AKT1 [8]. A recent
report also showed that AR-V7/AR3 transcriptional activity
can be inhibited by multiple AKT inhibitor and restoration
of PTEN activity [39]. These data suggested that AR-V7/AR3
and PI3K-AKT pathway might form a positive regulation loop
that contributes to PCa progression. This feedback loop is
distinct from the negative feedback loop that AReFL and
PI3K-AKT repress the activity of each other [40,41].
In addition to cell-cycle regulation, AR-V7/AR3 is a
critical factor for PCa metastasis. The AR3 transgenic
(AR3Tg) mouse generated by Sun and his colleague [27]
provides a new tool to study the role of AR-V7/AR3 in
prostate. Their microarray analysis revealed 414 genes that
were differentially expressed in AR3Tg compared to wild-
type animals. Gene set analysis indicated that AR3 regu-
lates multiple tumor-associated autocrine/paracrine fac-
tors including TGFb2 and IGF1. TGFb and IGF signaling are
well-known positive contributor to PCa progression. Inter-
estingly, a recent report showed that IGF-1R might be one
of the upstream signaling of AR. IGF signaling modulates
both AReFL and constitutively active AR-Vs activity via
receptor phosphorylation [42]. Thus, it is possible that AR-
V7/AR3 and TGFb2/IGF1 form a positive regulatory loop in
androgen independent PCa. As demonstrated in another
report, the link between AR-V7/AR3 and autocrine/endo-
crine signaling is that AR-V7/AR3 expression and activation
is associated with TNF-NFk-B signaling. NF-kB activates
AR-V7/AR3 modulates ADT drug enzalutamide resistance
[43]. Down-regulation of NF-kB signaling decreased AR-V7/
AR3 expression and restored the growth inhibiting effect of
anti-androgen drug [44]. Autocrine/paracrine pathway
signaling factors have been shown to have important
function on the proliferation, survival, migration andmaintenance of stem cell in various types of cancer
including PCa [45e48]. Thus, these data suggest that the
regulatory network of AR-V7/AR3 and autocrine/paracrine
signaling is critical for CRPC progression.
Accompanied with the elevated autocrine/paracrine
signaling, the expression of a number of EMT associated
genes including N-cadherin, vimentin, snail and twist were
also increased in AR-V7/AR3 overexpressed PCa cells and
AR3Tg animals [27]. These finding were further validated by
another group in multiple PCa cell lines. Overexpression of
AR-V7/AR3 in LNCaP and DU145 cells led to upregulation of
EMT markers fibronectin and ZEB1, respectively. Wound
healing assay showed that AR-V7/AR3 is able to promote
cell migration [26]. The correlation of AR-V7/AR3 and EMT
markers highly suggest a role of AR-V7/AR3 in PCa metas-
tasis [26,27,49]. In addition to EMT genes, stem cell signa-
tures genes were also observed to be increased in AR3Tg
prostate [27]. In consistence with the observations in
AR3Tg, knocking down of AR-V7/AR3, but not AReFL,
reduced the expression of stem cell marker genes Nanog
and Oct4 [26]. Overexpression of AR-V7/AR3 in PCa cells
promote prostasphere formation [26]. In summary, these
data suggest that AR-V7/AR3 contributes to PCa metastasis
and mCRPC progression through promoting the process of
EMT and acquiring stem cell properties.
2.2. Epigenetic regulation
Epigenetic regulation refers to dynamic alternations of the
molecule function without the change of DNA sequence.
Epigenetic regulation including DNA methylation, histone
modification, microRNA and long non-coding RNA and other
non DNA sequence alterations lead to molecular changes.
The importance of epigenetics regulation in cancers
including PCs has long been discovered [50]. Average DNA
methylation and histone methyltransferase EZH2 level are
increased in mCRPC [51e53]. This up-regulation of epige-
netic elements play critical roles in PCa progression and the
development of mCRPC [54]. AR has recently been shown
contribute to the epigenetic regulation in multiple aspects.
AR can recruit epigenetic co-activator/repressor to modu-
late certain genes expression. Association of AR with his-
tone demethylase LSD1 and JMJC is critical for downstream
androgen responsive genes expression [55]. Epigenetic
factor EZH2 acts as a coactivator of AR and the interaction
is critical for mCRPC [53]. AR is not only able to cooperate
with protein. A recent finding showed that AR bound to
lncRNA PRNCR1 and PCEGM1 which enhance both androgen
dependent and androgen independent AR regulatory pro-
gram and PCa proliferation [56]. In addition to cooperate
with epigenetic factors, AR is also able to regulate gene
expression via modulating epigenetic factors expression. A
study showed that AR is able to regulate EZH2 expression
through modulating miR-101 expression [57]. Androgen
induced miR-21 upregulation was shown to play important
roles in hormone-dependent and hormone-independent
PCa growth [58]. The close relationship of AR and epige-
netic factors opened a new window of how AR-Vs and
epigenetic factors cooperate. Due to the lack of C-terminus
ligand binding domain, AR-Vs may exert distinct roles in
epigenetic regulation compared with AReFL. Indeed, a few
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role of AR-Vs in epigenetic regulation. Microarray and real-
time PCR data in AR3Tg mouse model revealed that miR-29
expression was decreased when compared with the
wild-type control [27]. MiR-29 is a critical tumor suppressor
microRNA which was reported to be down-regulated in
various types of cancer. MiR-29 serves as a tumor suppressor
which is involved in multiple tumor related pathways
including immune regulation, cell proliferation, cell
senescence, apoptosis, and metastasis [59]. In addition to
target traditional tumor-related pathways, miR-29 is also
able to target epigenetic factor DNA methyltransferase
(DNMT) [59]. DNMT is responsible for establishing and
maintaining DNA methylation and the pattern of DNA
methylation is critical for cancer progression. In consist
with the hypothesis that AR-V7/AR3 may regulate DNMT
expression via miR-29, a recent report showed that DNMT
expression and AR-V7/AR3 expression were shown cooper-
atively up-regulated in 22Rv1 androgen independent cells
with long term bicalutamide treatment [60]. Interestingly,
this report also showed that DNMT activity was significantly
decreased after addition of androgen, suggesting AReFL
and AR-Vs may have distinct roles in regulating DNMT ac-
tivity. In conclusion, these data suggested that AR-V7/AR3
may regulate multiple PCa progression pathways via
modulating miR-29.2.3. AR-Vs and therapeutic response
Multiple lines of evidence indicated that AR-Vs is respon-
sible for ADT therapy (bicalutamide and enzalutamide)
resistance. Knockdown of AR-Vs, but not AReFL, decreased
androgen-independent PCa cells growth under bicaluta-
mide or enzalutamide treatment [25]. The landmark of AR-
Vs and ADT resistance in PCa patients is a study on 62 pa-
tients showed that detection of AR-V7 transcript in pooled
epithelial cell adhesion molecule (EpCAM)-positive circu-
lating tumor cells (CTCs) of men with progressive mCRPC
was associated with resistance to the AR signaling inhibitors
abiraterone and enzalutamide [17]. A subsequent study on
161 men with mCRPC showed that nuclear expression of AR-
V7 protein were found in CTCs from 18% of patients. Pa-
tients who had AR-V7epositive CTCs were resistant to
treatment of AR signaling inhibition but still responsive to
taxane treatment [61]. These studies suggest that AR-V7
could represent a biomarker to guide treatment selection
in mCRPC.
AR-Vs not only contribute to ADT resistance, but may
also be associated with other drug resistance, such as
chemotherapy drugs taxane. Taxane compounds, including
paclitaxel, docetaxel and cabazitaxel, are one of the few
effective chemotherapy treatments for mCRPC [62,63].
However, taxane chemotherapy only offer a limited survival
benefit (3e6 months average) due to the drug resistance
developed in mCRPC patients.
The action of taxane drugs is primary by disrupting
microtubule function. Taxanes stabilize tubulin polymer
and affect microtubule dynamic, thereby inhibiting cell
division and microtubule-dependent protein trafficking.
Microtubule-dependent AR trafficking is critical for AReFL
nuclear relocalization and activation. Evidence showedthat microtubule binding of AR is mediated by the C-ter-
minal of AR [32]. Because AR-V7 lacks the C-terminal
domain, the nuclear localization, transcriptional activity,
and tumor-promoting function of AR-V7 is not affected by
taxane treatment [32]. Thus, AR-V7 may not be sensitive to
taxane-induced microtubule stabilization and partially
responsible for the resistance to taxane. Despite these
findings in preclinical studies, the role of AR variants in
taxane resistance has yet to be established in clinical study.
Two small scale studies showed that expression of AR-V7 in
circulating tumor cells is not associated with taxane resis-
tance in mCRPC patients [64,65]. However, it is possible
that AR-Vs served as an alternative pathway that is able to
escape from the drug targeting mechanism thereby exert-
ing its function on cell proliferating and metastasis. In
addition to dodge the drug targeting, AR-Vs may also play a
role in well-established general resistance mechanism such
as increased drug efflux rate, alternation in drug meta-
bolism [66]. Reports showed that AR-V7/AR3 is able to
trigger stem-cell like feature in vitro and in vivo [26,27]. It
is conceivable that stem-cell like cancer cells generally
have overexpression of drug efflux transporters and up-
regulated anti-apoptotic signaling pathways thus resistant
to chemotherapies. In terms of metabolic regulation, the
presence of AR-V7/AR3 was shown strongly associated with
the down-regulation of citrate level and gains of function in
oxygen poor environment. Both factors are closely associ-
ated with cancer progression and are key characteristic of
mCRPC [67].
AR-Vs expression is higher in the more aggressive
androgen deprived CWR-R1 and 22Rv1 cell compared with
less aggressive LNCaP and its derivative cell lines.
AR-V7/AR3 is also associated with multiple drug resistance
as previously mentioned. These results suggest that various
stress environment may selectively enhance AR-Vs expres-
sion. Multiple mechanisms may be involved in up-regulation
of AR-Vs during PCs progression given the high degree of
complexity and heterogeneity in both morphological and
molecular level [68]. Deregulation of AR-Vs could be either
through up-regulate AR-Vs expression in all PCa population
or select AR-Vs positive population under drug treatment.
Thus, it is possible that drug resistance raised from minor
subpopulation that contain high level of AR-Vs which
already present in the tumor before treatment. In 22Rv1
androgen-independent PCa cells, AR-V7 expression
increased after long term bicalutamide treatment, sug-
gesting the enrichment of AR-V7 in drug-resistant popula-
tion [60]. Recent clinical reports suggest the concept that
cross-resistance is exist for patients under enzalutamide
treatments who have been previously treated with taxane
compound [69,70]. These findings raised the possibility that
taxane might provide a pre-selection for a drug-resistant
subpopulation. Whether AR-Vs activity is responsible for
the survival of the drug-resistant subpopulation needs to be
further determined. The drug resistance property of AR-Vs
makes it an important research topic in development of
new drugs targeting AR. In recent years, much more effort
was putting on the development of new compound target-
ing both AReFL and AR-Vs. A new compound EPI-001 tar-
geting N-terminal domain of AR was capable of blocking
both AReFL and AR-Vs transcriptional activity and inhibit
mCRPC growth in mouse xenografts [71]. Some other new
182 J. Xu, Y. Qiuandrogen signaling inhibitors, such as galeterone and ASC-
J9, displayed better efficacy in preclinical models
compared to enzalutamide, possibly due to that they can
inhibit both AR and AR-V activity [72,73]. Another new
compound, a pan-BET degrader ARV-771, was shown
effectively inhibit both AReFL and AR-Vs signaling in PCa
cells and lead to tumor regression in CRPC xenograft model
[74]. These compounds may potentially become new ther-
apeutic to overcome the AR-V induced drug resistance in
mCRPC.
3. Perspectives
AR-Vs have emerged as critical players in PCa progression
and therapeutic resistance through regulating both canon-
ical AR signature genes as well as distinct cell cycle related
genes unique for AR-Vs under androgen depleted conditions
(Fig. 1). Expression of AR-V7/AR3 in circulating tumor cells
could be used as a predictive biomarker for therapeutic
response to guide treatment selection. However, mecha-
nisms by which AR-Vs contribute to the development of
mCRPC and drug resistance have yet to be fully understood.
Further investigation is needed to elucidate the functional
interaction between AR and AR-Vs given that the level of
AR-Vs transcripts relative to AReFL is extremely low. It is
still unclear whether AR-Vs protein expression is correlated
with their transcript level due to limited success in devel-
opment of the specific antibodies for other variants besides
AR-V7. It is conceivable that the expression pattern of
AR-Vs could be very dynamic in response to various intra-
cellular and extracellular cues. The dynamic repertoire of
AReFL and AR-Vs may provide a sophistic regulatory system
to orchestrate cellular responses to androgens and other
extracellular stimuli. In addition to their ability to directly
regulate gene transcription independently, cooperatively
or competitively with AReFL, AR-Vs may play a role inFigure 1 Proposed model of the role of AR-V7/AR3 in
mCRPC. Upon androgen ablation, changes of genetic stability,
transcription/splicing and epigenetic regulation alter the
expression and activity of AR-V7. In addition to canonical
AReFL regulated genes, AR-V7 is able to regulate a subset
distinct target genes to promote metastasis, cell survival and
growth, and metabolic alteration in prostate cancer cells
mCRPC: metastatic castration resistant prostate cancer.epigenetic regulation by modulating non-coding RNAs and
chromatin remodeling. Facilitated by cutting edge tech-
nologies (such as single-cell sequencing and imaging anal-
ysis), we would better understand the role of AR-Vs in PCa
progression and therapeutic resistance.
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